Universal Beteiligungs und Servicegesellschaft mbH Purchases 149,777 Shares of Hinge Health Inc. $HNGE

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Hinge Health by 581.7%, buying 149,777 shares to hold 175,523 shares (about 0.22% of the company) valued at roughly $8.15 million.
• Insiders have been selling: President James Pursley and CFO James Budge sold shares on March 23, and insiders have disposed of 442,670 shares worth about $18.79 million over the past three months.
• Fundamentals and sentiment are positive: Hinge Health beat Q4 estimates (EPS $0.49 vs $0.04; revenue $170.7M vs $157.3M), and analysts maintain a largely bullish stance with a consensus price target of $56.73.

Universal Beteiligungs und Servicegesellschaft mbH grew its position in Hinge Health Inc. (NYSE:HNGE - Free Report) by 581.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 175,523 shares of the company's stock after purchasing an additional 149,777 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.22% of Hinge Health worth $8,153,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. First Horizon Corp raised its stake in Hinge Health by 163.9% during the fourth quarter. First Horizon Corp now owns 855 shares of the company's stock worth $40,000 after buying an additional 531 shares during the last quarter. Sandler Capital Management boosted its position in Hinge Health by 1.4% during the third quarter. Sandler Capital Management now owns 52,728 shares of the company's stock valued at $2,588,000 after acquiring an additional 728 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Hinge Health during the third quarter valued at $37,000. Jones Financial Companies Lllp grew its holdings in Hinge Health by 348.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,120 shares of the company's stock worth $54,000 after acquiring an additional 870 shares during the period. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Hinge Health in the 3rd quarter worth about $49,000.

Insider Transactions at Hinge Health

In other Hinge Health news, President James Pursley sold 15,000 shares of the firm's stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $42.26, for a total value of $633,900.00. Following the completion of the sale, the president owned 732,104 shares of the company's stock, valued at approximately $30,938,715.04. This trade represents a 2.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO James Budge sold 11,006 shares of the business's stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $42.26, for a total value of $465,113.56. Following the sale, the chief financial officer owned 401,427 shares of the company's stock, valued at approximately $16,964,305.02. This represents a 2.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 442,670 shares of company stock worth $18,786,901 in the last three months.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HNGE. Wells Fargo & Company initiated coverage on Hinge Health in a research note on Thursday, January 8th. They issued an "overweight" rating and a $68.00 price objective on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $59.00 target price on shares of Hinge Health in a research note on Wednesday, February 11th. Royal Bank Of Canada lifted their target price on Hinge Health from $50.00 to $55.00 and gave the stock an "outperform" rating in a report on Wednesday, March 11th. KeyCorp set a $55.00 price target on Hinge Health in a research note on Wednesday, February 11th. Finally, Wall Street Zen upgraded Hinge Health from a "hold" rating to a "buy" rating in a report on Saturday, March 7th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $56.73.

Hinge Health Trading Down 0.3%

Shares of NYSE HNGE opened at $44.14 on Monday. The firm has a market capitalization of $3.48 billion and a P/E ratio of -3.45. The firm's 50-day moving average price is $41.68 and its 200-day moving average price is $44.10. Hinge Health Inc. has a 1-year low of $30.08 and a 1-year high of $62.18.

Hinge Health (NYSE:HNGE - Get Free Report) last issued its earnings results on Tuesday, February 10th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.04 by $0.45. The firm had revenue of $170.73 million during the quarter, compared to analyst estimates of $157.31 million. The business's revenue was up 45.5% on a year-over-year basis. Equities research analysts forecast that Hinge Health Inc. will post 0.78 EPS for the current year.

About Hinge Health

Hinge Health NYSE: HNGE is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company's platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.